FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

UniQure must run one other research to show that its gene therapy “truly helps individuals with Huntington’s disease,” a senior U.S. Meals and Drug Administration official stated on a name with reporters Thursday.

The official, who requested anonymity earlier than discussing delicate info, confirmed the company has requested the corporate to run a placebo managed trial of its treatment, which is run immediately into the mind. UniQure has stated that sort of research is not moral as a result of it will require placing individuals beneath common anesthesia for hours, a characterization the official disputed.

“So what is de facto occurring? UniQure is the newest firm to make a failed therapy for Huntington’s sufferers,” the official stated. “They seemingly acknowledge or perceive at some deep degree that their trial failed years in the past, and as a substitute of doing the fitting factor and operating the proper medical research, UniQure is performing a distorted or manipulated comparability within the thoughts of FDA.”

The feedback mark the newest improvement in a messy public spat between UniQure and the FDA, and because the company comes beneath fireplace for a variety of current drug approval utility rejections, together with some the place corporations have accused it of going again on earlier steerage. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Fast final week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary did not title UniQure however described its treatment.

UniQure then accused the FDA of reversing its stance that the corporate’s medical trial information could be enough to hunt approval. UniQure’s research used an outdoor database to measure how sufferers with Huntington’s disease would possibly decline with out treatment, generally known as an exterior management. UniQure has stated it would not be possible to run a true randomized, double-blind placebo-controlled research, thought-about the gold commonplace, as a result of it would not be moral to make individuals bear a sham hours-long mind surgical procedure.

The FDA official stated the company “by no means agreed to just accept this distorted comparability” and the FDA “by no means makes such assurances.” As a substitute, the “FDA will all the time say, ‘Effectively, now we have to see the information once we get it.'”

UniQure in a assertion stated it is “assured within the energy of the information now we have submitted to the FDA” and it shares “the administration’s aim of creating significant therapies for sufferers affected by uncommon ailments.”

“The current statements made by nameless FDA sources to the press have been extremely irregular, unprecedented, and are incomplete or fully incorrect,” the corporate stated. “We don’t consider they replicate a honest and trustworthy studying of the paperwork now we have submitted or these now we have obtained from the company.”

The corporate’s inventory rose 18% on Thursday and has fallen 56% this yr as of Thursday’s shut.